Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Repligen Corporation

RGEN
Current price
150.62 USD +6.7 USD (+4.66%)
Last closed 142.44 USD
ISIN US7599161095
Sector Healthcare
Industry Medical Instruments & Supplies
Exchange NASDAQ
Capitalization 9 015 816 192 USD
Yield for 12 month -20.70 %
1Y
3Y
5Y
10Y
15Y
RGEN
21.11.2021 - 28.11.2021

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. Address: Building 1, Waltham, MA, United States, 02453

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

192.42 USD

P/E ratio

Dividend Yield

Current Year

+638 764 000 USD

Last Year

+801 536 000 USD

Current Quarter

+154 871 000 USD

Last Quarter

+154 073 000 USD

Current Year

+284 247 000 USD

Last Year

+455 706 000 USD

Current Quarter

+77 488 000 USD

Last Quarter

+68 773 000 USD

Key Figures RGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 100 456 000 USD
Operating Margin TTM -2.22 %
Price to Earnings
Return On Assets TTM 0.20 %
PEG Ratio 2.59
Return On Equity TTM -0.10 %
Wall Street Target Price 192.42 USD
Revenue TTM 639 915 008 USD
Book Value 35.53 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 9.70 %
Dividend Yield
Gross Profit TTM 455 706 000 USD
Earnings per share -0.030 USD
Diluted Eps TTM -0.030 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY -83.00 %
Profit Margin -0.33 %

Dividend Analytics RGEN

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History RGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor
Payout Ratio
Last Split Date

Stock Valuation RGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 98.04
Enterprise Value Revenue 13.52
Price Sales TTM 14.09
Enterprise Value EBITDA 82.43
Price Book MRQ 4.35

Financials RGEN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators RGEN

For 52 weeks

113.50 USD 211.13 USD
50 Day MA 142.41 USD
Shares Short Prior Month 3 425 303
200 Day MA 152.30 USD
Short Ratio 4.88
Shares Short 3 299 852
Short Percent 6.89 %